Firmonertinib Clinical Trials

3 actively recruiting trials across 1 location

▲ +1 trial since June 2026

Also known as: AST2818

Pipeline

Phase 2: 1Phase 3: 1Phase 4: 1

Top Sponsors

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology1
Hunan Cancer Hospital1
ArriVent BioPharma, Inc.1

Indications

Cancer3
EGFR Uncommon Mutations2
Lung Cancer2
Stage III1
Intrathecal Chemotherapy1

Other2 trials

Firmonertinib Combined With Definitive Radiotherapy in Stage III Unresectable EGFR Uncommon Mutant Pulmonary Adenocarcinoma

Phase 2

Firmonertinib Combined With Intrathecal Injection for the Treatment of EGFR Mutant NSCLC With Leptomeningeal Metastases

Phase 4

Los Angeles, California1 trial

Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

USC/Norris Comprehensive Cancer Center

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.